Post-earnings recap
Reported
Mon, Apr 2, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Soleno Therapeutics is still in a challenging position, as they reported a loss per share without providing revenue figures. The stock fell 3.47% in response, reflecting investor concern over the lack of guidance and clarity on future performance. The focus on development programs suggests that the company is prioritizing long-term growth over short-term results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance. They emphasized the importance of their development pipeline but did not offer specific forecasts.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing development programs.